GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » Gross Margin %

ViroGates A/S (OCSE:VIRO) Gross Margin % : 78.52% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. ViroGates A/S's Gross Profit for the three months ended in Mar. 2024 was kr1.21 Mil. ViroGates A/S's Revenue for the three months ended in Mar. 2024 was kr1.54 Mil. Therefore, ViroGates A/S's Gross Margin % for the quarter that ended in Mar. 2024 was 78.52%.

Warning Sign:

ViroGates A/S gross margin has been in long-term decline. The average rate of decline per year is -1.9%.


The historical rank and industry rank for ViroGates A/S's Gross Margin % or its related term are showing as below:

OCSE:VIRO' s Gross Margin % Range Over the Past 10 Years
Min: 77.35   Med: 86.09   Max: 90.59
Current: 82.41


During the past 8 years, the highest Gross Margin % of ViroGates A/S was 90.59%. The lowest was 77.35%. And the median was 86.09%.

OCSE:VIRO's Gross Margin % is ranked better than
91.58% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.295 vs OCSE:VIRO: 82.41

ViroGates A/S had a gross margin of 78.52% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for ViroGates A/S was -1.90% per year.


ViroGates A/S Gross Margin % Historical Data

The historical data trend for ViroGates A/S's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates A/S Gross Margin % Chart

ViroGates A/S Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 89.28 78.26 77.35 83.28 83.08

ViroGates A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.21 80.62 84.14 85.01 78.52

Competitive Comparison of ViroGates A/S's Gross Margin %

For the Medical Devices subindustry, ViroGates A/S's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates A/S's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates A/S's Gross Margin % distribution charts can be found below:

* The bar in red indicates where ViroGates A/S's Gross Margin % falls into.



ViroGates A/S Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

ViroGates A/S's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=5.8 / 6.987
=(Revenue - Cost of Goods Sold) / Revenue
=(6.987 - 1.182) / 6.987
=83.08 %

ViroGates A/S's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=1.2 / 1.536
=(Revenue - Cost of Goods Sold) / Revenue
=(1.536 - 0.33) / 1.536
=78.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


ViroGates A/S  (OCSE:VIRO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ViroGates A/S had a gross margin of 78.52% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


ViroGates A/S Gross Margin % Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroGates A/S (OCSE:VIRO) Business Description

Traded in Other Exchanges
N/A
Address
Banevaenget 13, Birkerod, DNK, DK-3460
ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates A/S (OCSE:VIRO) Headlines

No Headlines